Pharmaceutical Industry Updates: Product Applications, Shareholder Meetings, and Financial Performance
①Celltrion applies for European product approval for CT-P47 (Roactemra biosimilar) = Celltrion announced on the 13th that it has applied for European product approval for CT-P47 (Roactemra biosimilar). The indications are △ rheumatoid arthritis △ giant cell arteritis △ systemic type juvenile arthritis △ polyarticular type juvenile arthritis △ cytokine release syndrome △ coronavirus -19 […]
Samsung Pharmaceuticals Reports Positive Results of Phase 2 Clinical Trial for Alzheimer’s Treatment GV1001
Samsung Pharmaceuticals said in a press release that the results of the Phase 2 clinical trial of “GV1001”, a drug for the treatment of Alzheimer’s disease for which the domestic development and commercialization rights have been transferred from Gemvax Encael ( Gemvax) in May last year, showed that the control group given only donepezil had […]
GV1001: A Promising New Treatment for Alzheimer’s Disease
[이미지 제공 = 젬백스앤카엘] [Il giornalista del quotidiano Kang Hyun-min]The research results showed that GV1001, which was developed by the new drug development company Gemvax & Kael (hereinafter referred to as Gemvax) as a treatment for Alzheimer’s disease, produces an anti-aging effect, suppressing cellular aging and neurodegeneration and increase in survival period. Gemvax announced that […]
